- Home
- KYNB vs CCM Comparison
KYNB vs CCM Comparison
Compare KYNB & CCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYNB | CCM |
|---|---|---|
| Founded | 1993 | 1997 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 23.0M |
| IPO Year | 2014 | 2009 |
Fundamental Metrics
Financial Performance| Metric | KYNB | CCM |
|---|---|---|
| Price | $8.11 | $4.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.5K | ★ 66.4K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9552.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,440,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.32 | $3.18 |
| 52 Week High | $9.58 | $6.98 |
Technical Indicators
Market Signals| Indicator | KYNB | CCM |
|---|---|---|
| Relative Strength Index (RSI) | 71.71 | 53.37 |
| Support Level | $6.61 | $4.41 |
| Resistance Level | $8.99 | $5.42 |
| Average True Range (ATR) | 0.31 | 0.48 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 99.24 | 45.46 |
Price Performance
Historical ComparisonAbout KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
About CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.